

# Shinya Kimura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8003149/publications.pdf>

Version: 2024-02-01

209  
papers

3,134  
citations

236925

25  
h-index

206112

48  
g-index

220  
all docs

220  
docs citations

220  
times ranked

4501  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14907-14912.	7.1	310
2	Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematology, 2015, 2, e528-e535.	4.6	261
3	NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood, 2005, 106, 3948-3954.	1.4	232
4	Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Advances, 2018, 2, 2744-2754.	5.2	106
5	Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 353-360.e1.	0.4	89
6	Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leukemia Research, 2008, 32, 980-983.	0.8	78
7	Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study. Cancer Science, 2016, 107, 162-167.	3.9	67
8	2-Hydroxypropyl- $\beta$ -Cyclodextrin Acts as a Novel Anticancer Agent. PLoS ONE, 2015, 10, e0141946.	2.5	65
9	Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematology, 2020, 7, e218-e225.	4.6	65
10	Neuroprotective Efficacy of a New Brain-Penetrating C-Abl Inhibitor in a Murine Parkinson's Disease Model. PLoS ONE, 2013, 8, e65129.	2.5	62
11	Saturated Fatty Acid Increases Lung Macrophages and Augments House Dust Mite-Induced Airway Inflammation in Mice Fed with High-Fat Diet. Inflammation, 2017, 40, 1072-1086.	3.8	61
12	Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Advances, 2022, 6, 238-247.	5.2	61
13	Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer, 2010, 116, 2665-2672.	4.1	45
14	SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer. OncoTargets and Therapy, 2016, Volume 9, 6663-6668.	2.0	45
15	Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert Review of Anticancer Therapy, 2008, 8, 1387-1398.	2.4	42
16	Inhibition of HIV-1 entry by the tricyclic coumarin GUT-70 through the modification of membrane fluidity. Biochemical and Biophysical Research Communications, 2015, 457, 288-294.	2.1	41
17	Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. International Journal of Hematology, 2015, 102, 379-382.	1.6	38
18	Efficacy of the dual PI3K and mTOR inhibitor NVP-BE225 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Cancer Biology and Therapy, 2014, 15, 207-215.	3.4	37

#	ARTICLE	IF	CITATIONS
19	Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1798-1804.	1.9	37
20	Interleukin-33 from Monocytes Recruited to the Lung Contributes to House Dust Mite-Induced Airway Inflammation in a Mouse Model. <i>PLoS ONE</i> , 2016, 11, e0157571.	2.5	35
21	Allelic Polymorphisms of <i>KIR</i> s and <i>HLA</i> s Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML. <i>Cancer Immunology Research</i> , 2018, 6, 745-754.	3.4	31
22	Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells. <i>Cancer Science</i> , 2016, 107, 1029-1038.	3.9	30
23	Clinical impact of the CONUT score in patients with multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 113-119.	1.8	30
24	Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e902-e911.	4.6	30
25	Ever-advancing chronic myeloid leukemia treatment. <i>International Journal of Clinical Oncology</i> , 2014, 19, 3-9.	2.2	29
26	Rapid quantitation of immunoglobulin G antibodies specific for blood group antigens A and B by surface plasmon resonance. <i>Transfusion</i> , 2005, 45, 56-62.	1.6	28
27	Preclinical activity of the novel cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC 209 in acute myeloid leukemia: Implications for leukemia therapy. <i>Cancer Science</i> , 2015, 106, 1705-1713.	3.9	27
28	Automated DNA extraction using cellulose magnetic beads can improve EGFR point mutation detection with liquid biopsy by efficiently recovering short and long DNA fragments. <i>Oncotarget</i> , 2018, 9, 25181-25192.	1.8	27
29	Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100. <i>Blood</i> , 2020, 136, 871-884.	1.4	27
30	Fully automated and super-rapid system for the detection of JAK2V617F mutation. <i>Leukemia Research</i> , 2008, 32, 1462-1467.	0.8	26
31	Development of a Novel, Fully-Automated Genotyping System: Principle and Applications. <i>Sensors</i> , 2012, 12, 16614-16627.	3.8	26
32	Mechanisms of acquired resistance to afatinib clarified with liquid biopsy. <i>PLoS ONE</i> , 2018, 13, e0209384.	2.5	25
33	Investigation of appropriate pre-analytical procedure for circulating free DNA from liquid biopsy. <i>Oncotarget</i> , 2018, 9, 31904-31914.	1.8	25
34	Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 94-105.	4.1	23
35	Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 370-374.	0.4	23
36	Newly Designed Silica-Containing Redox Nanoparticles for Oral Delivery of Novel TOP2 Catalytic Inhibitor for Treating Colon Cancer. <i>Advanced Healthcare Materials</i> , 2017, 6, 1700428.	7.6	22

#	ARTICLE	IF	CITATIONS
37	Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). <i>International Journal of Clinical Oncology</i> , 2019, 24, 445-453.	2.2	22
38	The non-antibiotic macrolide EM900 attenuates HDM and poly(I:C)-induced airway inflammation with inhibition of macrophages in a mouse model. <i>Inflammation Research</i> , 2020, 69, 139-151.	4.0	21
39	Role of cancer immunology in chronic myelogenous leukemia. <i>Leukemia Research</i> , 2020, 88, 106273.	0.8	19
40	Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia. <i>International Journal of Hematology</i> , 2019, 110, 566-574.	1.6	18
41	Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. <i>Oncology Reports</i> , 2015, 33, 391-396.	2.6	17
42	Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. <i>International Journal of Clinical Oncology</i> , 2018, 23, 974-979.	2.2	17
43	C/EBP $\beta$ is a critical mediator of IFN- $\gamma$ -induced exhaustion of chronic myeloid leukemia stem cells. <i>Blood Advances</i> , 2019, 3, 476-488.	5.2	17
44	Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. <i>Cancer Letters</i> , 2011, 312, 228-234.	7.2	16
45	Coexistence of lung cancer and immunoglobulin G4-related lung disease in a nodule: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 113.	0.8	16
46	Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 28547-28560.	1.8	16
47	Human $\gamma\delta$ T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 573, 132-139.	2.1	16
48	Correlation between Plasma DNA and Tumor Status in an Animal Model. <i>PLoS ONE</i> , 2014, 9, e111881.	2.5	15
49	$\beta_2$ adrenergic agonist attenuates house dust mite-induced allergic airway inflammation through dendritic cells. <i>BMC Immunology</i> , 2014, 15, 39.	2.2	15
50	Isopentenyl pyrophosphate secreted from Zoledronate-stimulated myeloma cells, activates the chemotaxis of $\gamma\delta$ T cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 650-655.	2.1	15
51	Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia. <i>Stem Cell Investigation</i> , 2016, 3, 36-36.	3.0	15
52	Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of afatinib. <i>Journal of Pharmaceutical Analysis</i> , 2019, 9, 49-54.	5.3	15
53	Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2020, 112, 41-45.	1.6	15
54	Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia. <i>PLoS ONE</i> , 2014, 9, e99080.	2.5	15

#	ARTICLE	IF	CITATIONS
55	Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy. <i>Anticancer Research</i> , 2018, 38, 3559-3566.	1.1	14
56	Development of a sandwich enzyme-linked immunosorbent assay for the quantification of ponatinib in serum. <i>Analytical Biochemistry</i> , 2019, 571, 14-20.	2.4	14
57	HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1439-1450.	7.2	14
58	<i>HLA</i> Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 142-149.	4.1	14
59	Single-step, label-free quantification of antibody in human serum for clinical applications based on localized surface plasmon resonance. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 889-895.	3.3	13
60	Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. <i>Leukemia Research</i> , 2016, 40, 68-76.	0.8	13
61	ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2014, 100, 611-614.	1.6	12
62	Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1203-1210.	2.2	12
63	Tocilizumab for severe cytokine release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 324-327.	1.7	11
64	Current state of therapeutic development for rare cancers in Japan, and proposals for improvement. <i>Cancer Science</i> , 2018, 109, 1731-1737.	3.9	11
65	Origin of circulating free DNA in patients with lung cancer. <i>PLoS ONE</i> , 2020, 15, e0235611.	2.5	10
66	Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer. <i>Lung Cancer</i> , 2017, 110, 35-41.	2.0	10
67	Association of orexin receptor antagonists with falls during hospitalization. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 809-813.	1.5	10
68	A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib. <i>PLoS ONE</i> , 2019, 14, e0207170.	2.5	9
69	&lt;p&gt;Biomarkers for Overweight in Adult-Onset Asthma&lt;/p&gt;. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 409-414.	3.4	9
70	Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. <i>International Journal of Hematology</i> , 2020, 112, 115-117.	1.6	9
71	Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience. <i>Hematological Oncology</i> , 2021, 39, 549-557.	1.7	9
72	Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients. <i>Cancer Science</i> , 2020, 111, 2526-2535.	3.9	9

#	ARTICLE	IF	CITATIONS
73	The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma. <i>Oncotarget</i> , 2016, 7, 69625-69637.	1.8	9
74	&lt;p&gt;First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 2115-2126.	2.3	9
75	Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2021, 13, 5543.	3.7	9
76	Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. <i>Cancer Letters</i> , 2022, 526, 273-283.	7.2	9
77	̢2-microglobulin is unsuitable as an internal reference gene for the analysis of gene expression in human colorectal cancer. <i>Biomedical Reports</i> , 2013, 1, 193-196.	2.0	8
78	Surface chemical approach to single-step measurement of antibody in human serum using localized surface plasmon resonance biosensor on microtiter plate system. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 4527-4533.	3.7	8
79	Characteristics and prognosis of microscopic polyangiitis with bronchiectasis. <i>Journal of Thoracic Disease</i> , 2017, 9, 303-309.	1.4	8
80	Relationship between the duration of trimethoprim/sulfamethoxazole treatment and the clinical outcome of pulmonary nocardiosis. <i>Respiratory Investigation</i> , 2018, 56, 166-172.	1.8	8
81	Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2020, 20, 318.	2.0	8
82	The Nonantibiotic Macrolide EM900 Attenuates House Dust Mite-Induced Airway Inflammation in a Mouse Model of Obesity-Associated Asthma. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 665-674.	2.1	8
83	Folic Acid-Appended Hydroxypropyl-̢2-Cyclodextrin Exhibits Potent Antitumor Activity in Chronic Myeloid Leukemia Cells via Autophagic Cell Death. <i>Cancers</i> , 2021, 13, 5413.	3.7	8
84	Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin. <i>Anticancer Research</i> , 2016, 36, 95-102.	1.1	8
85	Disseminated Nocardiosis Caused by &lt;i&gt;Nocardia concava&lt;/i&gt; with Acute Respiratory Failure and Central Nervous System Involvement Treated with Linezolid. <i>Internal Medicine</i> , 2012, 51, 3281-3285.	0.7	7
86	Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy. <i>Leukemia Research</i> , 2016, 51, 11-18.	0.8	7
87	Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer. <i>Medical Oncology</i> , 2017, 34, 195.	2.5	7
88	Paraneoplastic Sarcoidosis in Multiple Myeloma. <i>Internal Medicine</i> , 2017, 56, 2049-2051.	0.7	7
89	The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group. <i>Internal Medicine</i> , 2018, 57, 17-23.	0.7	7
90	Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia. <i>Immunological Medicine</i> , 2020, 44, 1-8.	2.6	7

#	ARTICLE	IF	CITATIONS
91	Immune dysregulation syndrome with de novo CTLA4 germline mutation responsive to abatacept therapy. <i>International Journal of Hematology</i> , 2020, 111, 897-902.	1.6	7
92	Skeletal muscle is associated with exercise tolerance evaluated by cardiopulmonary exercise testing in Japanese patients with chronic obstructive pulmonary disease. <i>Scientific Reports</i> , 2021, 11, 15862.	3.3	7
93	A case of osimertinib-resistant lung adenocarcinoma responded effectively to alternating therapy. <i>Annals of Translational Medicine</i> , 2018, 6, 464-464.	1.7	7
94	Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 169-177.	3.4	7
95	Rapid sensitive analysis of IDH1 mutation in lower-grade gliomas by automated genetic typing involving a quenching probe. <i>Cancer Investigation</i> , 2016, 34, 12-15.	1.3	6
96	Automatic digital quantification of bone marrow myeloma volume in appendicular skeletons - clinical implications and prognostic significance. <i>Scientific Reports</i> , 2017, 7, 12885.	3.3	6
97	Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 43.	0.8	6
98	Epstein-Barr virus-related diffuse large B-cell lymphoma in mogamulizumab-treated adult T-cell leukemia with incomplete T-cell reconstitution. <i>International Journal of Hematology</i> , 2019, 109, 221-227.	1.6	6
99	Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2020, 111, 733-738.	1.6	6
100	Silylation of deoxynucleotide analog yields an orally available drug with anti-leukemia effects. <i>Molecular Cancer Therapeutics</i> , 2021, 20, molcanther.1125.2020.	4.1	6
101	Lenalidomide in combination with dexamethasone induced rhabdomyolysis in a multiple myeloma patient treated with pravastatin. <i>International Journal of Hematology</i> , 2011, 94, 216-217.	1.6	5
102	Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide. <i>Leukemia and Lymphoma</i> , 2018, 59, 2474-2477.	1.3	5
103	Three coexisting lymphomas in a single patient: composite lymphoma derived from a common germinal center B-cell precursor and unrelated discordant lymphoma. <i>International Journal of Hematology</i> , 2018, 107, 703-708.	1.6	5
104	Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells. <i>Investigational New Drugs</i> , 2020, 38, 1012-1019.	2.6	5
105	Association of Genetic Polymorphisms With Afatinib-induced Diarrhoea. <i>In Vivo</i> , 2020, 34, 1415-1419.	1.3	5
106	Terminal deoxynucleotidyl transferase (TdT) negative early T cell precursor acute lymphoblastic leukemia (ETP-ALL) with spontaneous acute kidney injury. <i>Annals of Hematology</i> , 2020, 99, 885-886.	1.8	5
107	Evaluation of olfactory dysfunction to estimate the presence of eosinophilic chronic rhinosinusitis in patients with asthma. <i>Respiratory Investigation</i> , 2021, 59, 126-134.	1.8	5
108	Efficacy of dupilumab and biomarkers for systemic corticosteroid naïve allergic bronchopulmonary mycosis. <i>Allergology International</i> , 2021, 70, 145-147.	3.3	5

#	ARTICLE	IF	CITATIONS
109	Acute Generalized Exanthematous Pustulosis Caused by Erlotinib in a Patient with Lung Cancer. Case Reports in Oncology, 2021, 14, 599-603.	0.7	5
110	A Low Body Mass Index Is Associated with Unsuccessful Treatment in Patients with Mycobacterium avium Complex Pulmonary Disease. Journal of Clinical Medicine, 2021, 10, 1576.	2.4	5
111	Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute. International Journal of Hematology, 2021, 114, 199-204.	1.6	5
112	Development of a Competitive Enzyme-Linked Immunosorbent Assay for the Determination of Sunitinib Unaffected by Light-Induced Isomerization. Biological and Pharmaceutical Bulletin, 2021, 44, 1565-1570.	1.4	5
113	Molecular Mechanism for Synergistic Anti-Leukemic Activity of Tyrosine Kinase Inhibitors and Glucocorticoids Against Ph+ALL. Blood, 2016, 128, 1059-1059.	1.4	5
114	AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer. Current Opinion in Investigational Drugs, 2010, 11, 1442-9.	2.3	5
115	RUNX1 transactivates <i>BCR-ABL1</i> expression in Philadelphia chromosome positive acute lymphoblastic leukemia. Cancer Science, 2022, 113, 529-539.	3.9	5
116	Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism. International Journal of Cancer, 2022, 150, 1184-1197.	5.1	5
117	Second Generation Abl Kinase Inhibitors and Novel Compounds to Eliminate the Bcr-Abl/T315I Clone. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1, 347-355.	1.6	4
118	Hairy Cell Leukemia with Systemic Lymphadenopathy: Detection of BRAF Mutations in Both Lymph Node and Peripheral Blood Specimens. Internal Medicine, 2015, 54, 1397-1402.	0.7	4
119	Evaluation of a cloud-based local-read paradigm for imaging evaluations in oncology clinical trials for lung cancer. Acta Radiologica Open, 2015, 4, 205846011558810.	0.6	4
120	Acute myeloid leukemia with t(3;8)(q26;q24) complicated by diabetes insipidus. Annals of Hematology, 2016, 95, 653-655.	1.8	4
121	Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients. Pathology and Oncology Research, 2017, 23, 181-188.	1.9	4
122	Pre-existing chronic interstitial pneumonia is a poor prognostic factor of Goodpasture's syndrome: a case report and review of the literature. Journal of Medical Case Reports, 2017, 11, 102.	0.8	4
123	Sjögren Syndrome Complicated with Cystic Lung Disease and Pulmonary Amyloidosis. Case Reports in Rheumatology, 2018, 2018, 1-5.	0.6	4
124	Immunohistochemical localization of afatinib in male rat intestines and skin after its oral administration. Acta Histochemica, 2019, 121, 151439.	1.8	4
125	Assessment of tumor volume and density as a measure of the response of advanced hepatocellular carcinoma to sorafenib: Application of automated measurements on computed tomography scans. JGH Open, 2020, 4, 145-152.	1.6	4
126	Development of an application for management of drug holidays in perioperative periods. Medicine (United States), 2020, 99, e20142.	1.0	4



#	ARTICLE	IF	CITATIONS
127	Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor. <i>International Journal of Hematology</i> , 2020, 112, 249-253.	1.6	4
128	Phosphorylated ERK1/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 667-671.	5.2	4
129	Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia. <i>Turkish Journal of Haematology</i> , 2021, 38, 83-85.	0.5	4
130	Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.. <i>Blood</i> , 2009, 114, 2166-2166.	1.4	4
131	The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease. <i>Blood</i> , 2019, 134, 1929-1929.	1.4	4
132	Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients. <i>Pathology and Oncology Research</i> , 2017, 23, 737-744.	1.9	3
133	Primary effusion lymphoma-like lymphoma with a T cell phenotype. <i>Annals of Hematology</i> , 2018, 97, 717-718.	1.8	3
134	Primary Pulmonary Colloid Adenocarcinoma: How Can We Obtain a Precise Diagnosis?. <i>Internal Medicine</i> , 2018, 57, 3637-3641.	0.7	3
135	Oral ulceration: an unusual manifestation of lymphomatoid granulomatosis. <i>Annals of Hematology</i> , 2019, 98, 1305-1307.	1.8	3
136	Surrogate Markers for Treatment-Free Remission in Patients With Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 785-790.	0.4	3
137	A methotrexate-associated lymphoproliferative disorder expressing CD10 and BCL6 with the IGH/CCND1 translocation. <i>Annals of Hematology</i> , 2020, 99, 2449-2451.	1.8	3
138	Clonality of HIV-1 and HTLV-1 Infected Cells in Naturally Coinfected Individuals. <i>Journal of Infectious Diseases</i> , 2022, 225, 317-326.	4.0	3
139	Aplastic Anemia in a Patient with Cronkhite-Canada Syndrome. <i>Internal Medicine</i> , 2021, 60, 1601-1605.	0.7	3
140	Pharmacological MEK inhibition promotes polyclonal T-cell reconstitution and suppresses xenogeneic GVHD. <i>Cellular Immunology</i> , 2021, 367, 104410.	3.0	3
141	Non-valvular Infective Endocarditis Caused by <i>Sarocladium kiliense</i> in an Immunocompromised Patient with Aplastic Anemia. <i>Internal Medicine</i> , 2022, 61, 1279-1283.	0.7	3
142	Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary Disease. <i>International Journal of COPD</i> , 2021, Volume 16, 3297-3307.	2.3	3
143	Clinical Implications of Determining Individualized Positive End-Expiratory Pressure Using Electrical Impedance Tomography in Post-Cardiac Surgery Patients: A Prospective, Non-Randomized Interventional Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3022.	2.4	3
144	Chronic and Asymptomatic Diffuse Alveolar Haemorrhage with Microscopic Polyangiitis: A Case Report and Review of the Literature. <i>Case Reports in Rheumatology</i> , 2016, 2016, 1-6.	0.6	2

#	ARTICLE	IF	CITATIONS
145	Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method. <i>International Journal of Hematology</i> , 2018, 108, 416-422.	1.6	2
146	Mesalazine-induced airway obstruction: Utility of pulmonary function testing in drug-induced lung diseases. <i>Respiratory Investigation</i> , 2019, 57, 611-614.	1.8	2
147	Japan's high-cost medical expense benefit system could be an obstacle to promoting generic imatinib. <i>Lancet Haematology</i> , 2019, 6, e498.	4.6	2
148	Monitoring of tumor cells by flow cytometry permits rapid evaluation of disease progression in monomorphic epitheliotropic intestinal T cell lymphoma. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 454-456.	1.5	2
149	Clinical impact of advanced chronic kidney disease in patients with non-HIV pulmonary cryptococcosis. <i>BMC Pulmonary Medicine</i> , 2020, 20, 116.	2.0	2
150	Clinical Manifestations of Allergic Bronchopulmonary Aspergillosis without Major Features of Asthma Diagnosed by the New Criteria in Japan. <i>Internal Medicine</i> , 2021, 60, 1251-1255.	0.7	2
151	Immune Thrombocytopenia Exacerbation After COVID-19 Vaccination in a Young Woman. <i>Cureus</i> , 2021, 13, e17942.	0.5	2
152	Severity of constipation related to palonosetron during first-line chemotherapy: a retrospective observational study. <i>Supportive Care in Cancer</i> , 2021, 29, 4723-4732.	2.2	2
153	Inhibition of Wnt/ $\beta$ -Catenin Signaling by AV65 Treatment Caused Cell Cycle Arrest and Induced Caspase-Independent or -Dependent Apoptosis in CML Cells. <i>Blood</i> , 2009, 114, 2184-2184.	1.4	2
154	Expression level of BTN3A1 on the surface of CD14+ monocytes is a potential predictor of T cell expansion efficiency. <i>Biochemical and Biophysical Research Communications</i> , 2022, 588, 47-54.	2.1	2
155	NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia. <i>International Journal of Hematology</i> , 2022, , 1.	1.6	2
156	5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10). <i>International Journal of Hematology</i> , 2017, 105, 692-696.	1.6	1
157	Plasma T790M and HGF as potential predictive markers for EGFR-TKI re-challenge. <i>Oncology Letters</i> , 2017, 13, 4939-4946.	1.8	1
158	Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion. <i>Internal Medicine</i> , 2018, 57, 855-860.	0.7	1
159	BCR-ABL1- and CBF $\beta$ -MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis. <i>Annals of Hematology</i> , 2019, 98, 2461-2462.	1.8	1
160	Locally distributed multicentric plasmacytomas in the ileum secondary to lymphoma chemoimmunotherapy. <i>Annals of Hematology</i> , 2019, 98, 1501-1503.	1.8	1
161	Venue of catheter insertion does not significantly impact the event of central line-associated bloodstream infection in patients with haematological diseases. <i>Infection Prevention in Practice</i> , 2020, 2, 100050.	1.3	1
162	Development of Acquired Hemophilia A After Treatment of Bronchial Asthma with Benralizumab. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 509-510.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Evolution of CML treatment. <i>International Journal of Hematology</i> , 2021, 113, 622-623.	1.6	1
164	Idiopathic eosinophilic pleurisy: A practical diagnostic approach. <i>Respiratory Medicine Case Reports</i> , 2021, 33, 101430.	0.4	1
165	An Autophagy Inhibitor, Chloroquine, Overcomes An Imatinib-Resistant T315I Mutant of Bcr/Abl, Whose Latent May Exist Before Imatinib Treatment.. <i>Blood</i> , 2009, 114, 2183-2183.	1.4	1
166	Osteoclasts Are Involved in the Maintenance of Dormant Leukemic Cells.. <i>Blood</i> , 2009, 114, 4245-4245.	1.4	1
167	Metabolic Shift In Hypoxia-Adapted CML Cells and Mechanisms Of Acquired Dasatinib Resistance Uncovered By Proteomic iTRAQ Profiling. <i>Blood</i> , 2013, 122, 3991-3991.	1.4	1
168	Successful Anti-TNF-Alpha Therapy for Crohn's Disease After Allogeneic Stem Cell Transplantation: A Case Report. <i>Tohoku Journal of Experimental Medicine</i> , 2020, 251, 81-85.	1.2	1
169	The Tricyclic Coumarin GUT-70 Induces Apoptosis and Cell Cycle Arrest Preferentially in Mantle Cell Lymphomas with Mutant p53.. <i>Blood</i> , 2009, 114, 1684-1684.	1.4	1
170	Concomitant Nephrotic Syndrome with Diffuse Large B-cell Lymphoma: A Case Report. <i>Tohoku Journal of Experimental Medicine</i> , 2020, 252, 153-157.	1.2	1
171	Integrated approach to functional analysis of an ERBB2 variant of unknown significance detected by a cancer gene panel test. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 121.	4.4	1
172	Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease. <i>Frontiers in Pediatrics</i> , 2021, 9, 670703.	1.9	1
173	Myeloid blast crisis in chronic myeloid leukemia with a unique deletion near the BCR/ABL breakpoint. <i>International Cancer Conference Journal</i> , 2015, 4, 26-28.	0.5	0
174	Acute myeloid leukemia with t(19;21)(q13;q22) and marked eosinophilia. <i>Annals of Hematology</i> , 2019, 98, 221-222.	1.8	0
175	Primary Chest Wall MYC/BCL6 Double-hit Lymphoma with t (3;7) (q27;p12) and t (8;14) (q24;q32) Translocations. <i>Internal Medicine</i> , 2019, 58, 2073-2077.	0.7	0
176	Is clinicopathological distinction of mucosa-associated lymphoid tissue lymphoma from Waldenström macroglobulinemia essential in MYD88 L265P mutation-positive cases?. <i>International Journal of Hematology</i> , 2019, 109, 247-248.	1.6	0
177	Epstein-Barr virus-positive diffuse large B cell lymphoma, not otherwise specified, carrying a t(19;22)(q13;q11) translocation. <i>Annals of Hematology</i> , 2020, 99, 389-390.	1.8	0
178	Does patient sex play a role in treatment-free remission in chronic myeloid leukemia?. <i>International Journal of Hematology</i> , 2020, 111, 903-903.	1.6	0
179	Accelerated Phase of Atypical Chronic Myeloid Leukemia with Severe Disseminated Intravascular Coagulation at Initial Presentation. <i>Internal Medicine</i> , 2020, 59, 1549-1553.	0.7	0
180	J-SKI will be able to elucidate whether the renal function recover or not after discontinuation of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2020, 112, 429-430.	1.6	0

#	ARTICLE	IF	CITATIONS
181	Prolonged gastric mucosal haemorrhage following azacitidine administration in a patient with myelodysplastic syndrome. <i>EJHaem</i> , 2021, 2, 653-654.	1.0	0
182	Immune dysregulation syndrome with cytotoxic T-lymphocyte antigen 4 mutation showing multiple central nervous system lesions. <i>Clinical and Experimental Neuroimmunology</i> , 0, , .	1.0	0
183	<i>Helicobacter cinaedi</i> bacteremia in a patient with primary central nervous system lymphoma. <i>EJHaem</i> , 0, , .	1.0	0
184	AV-65, a Novel Inhibitor of the Wnt/ $\beta$ -Catenin Signaling Pathway, Inhibits the Proliferation of Myeloma Cells.. <i>Blood</i> , 2009, 114, 2866-2866.	1.4	0
185	Hepatitis B Virus Reactivation in Malignant Lymphoma with Occult HBV Carrier.. <i>Blood</i> , 2009, 114, 4794-4794.	1.4	0
186	The Efficacy of Dual PI3K and mTOR Inhibitor, NVP-BEZ235 against BCR-ABL Positive Leukemia Cells Include ABL Kinase Domain Mutation in Combination with Nilotinib.. <i>Blood</i> , 2009, 114, 3784-3784.	1.4	0
187	Combined Effects of novel Heat Shock Protein 90 Inhibitor NVP-AUY922 and Nilotinib in a Random Mutagenesis Screen.. <i>Blood</i> , 2009, 114, 3765-3765.	1.4	0
188	Galectin-9 Ameliorates Acute GVHD by Inducing T-Cell Apoptosis and Increasing Regulatory T Cell.. <i>Blood</i> , 2009, 114, 1338-1338.	1.4	0
189	Automated and Rapid Detection of BCR-ABL Kinase Domain Mutations in IM Resistant Patients with Ph+ Leukemias.. <i>Blood</i> , 2009, 114, 2590-2590.	1.4	0
190	Galectin-9 Overcomes Various Types of Treatment Resistance through ATF-3/Noxa Pathway-Mediated Apoptosis In Chronic Myelogenous Leukemia. <i>Blood</i> , 2010, 116, 4930-4930.	1.4	0
191	The Anti-Proliferative Effects of Tricyclic Coumarin GUT-70 as An Hsp90 Inhibitor In Mantle Cell Lymphoma. <i>Blood</i> , 2010, 116, 3977-3977.	1.4	0
192	The Anti-Proliferative Effects of Hsp90 Inhibitor Tricyclic Coumarin GUT-70 and Geldanamycin Analog 17-DMAG in AML Cells in Hypoxia. <i>Blood</i> , 2011, 118, 2480-2480.	1.4	0
193	Combined Effects of a Pan-ABL1 Kinase Inhibitor, Ponatinib and Dasatinib Against T315I Mutant Forms of BCR-ABL1: In Vitro and In Vivo Studies. <i>Blood</i> , 2011, 118, 2482-2482.	1.4	0
194	Combining ABL1 Kinase Inhibitor, Ponatinib and the Histone Deacetylase (HDAC) Inhibitor Vorinostat: A Potential Treatment for BCR-ABL Positive Leukemia Cells. <i>Blood</i> , 2011, 118, 1403-1403.	1.4	0
195	Induction Of p53 Transcription and Apoptosis By XPO1 Inhibition In Mantle Cell Lymphoma. <i>Blood</i> , 2013, 122, 3825-3825.	1.4	0
196	Monitoring <i>EGFR</i> T790M with plasma DNA in lung cancer patients treated with EGFR tyrosine kinase inhibitor in prospective observational study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11014-11014.	1.6	0
197	Volume-based response evaluations with consensual lesion selection using cloud solutions in clinical trials: A pilot study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13538-e13538.	1.6	0
198	The Pathophysiological Significance and Therapeutic Targeting of PPM1D-Mediated Signaling in Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 2760-2760.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIs. , 2017, , 55-75.		0
200	Aberrant Regional DNA Hypermethylation As a Preventive and Therapeutic Target for Adult T-Cell Leukemia-Lymphoma. Blood, 2018, 132, 4175-4175.	1.4	0
201	The Presence and Possible Role of Virus-Host Chimeric Transcripts in Adult T-Cell Leukemia-Lymphoma. Blood, 2019, 134, 2779-2779.	1.4	0
202	Construction of Two Box-Like Head-and-Face Shields by Japanese Origami Folding for Use During the COVID-19 Pandemic. International Journal of General Medicine, 2020, Volume 13, 1669-1673.	1.8	0
203	A 45-Year-Old Man With Acute Chest Pain, Fever, and Dyspnea After Tooth Extraction. Chest, 2021, 160, e623-e628.	0.8	0
204	Favorable HLA Polymorphisms are Associated with Lower Molecular Relapse after Tyrosine Kinase Discontinuation in Patients with Chronic Myeloid Leukemia. Indian Journal of Hematology and Blood Transfusion, 0, , 1.	0.6	0
205	Origin of circulating free DNA in patients with lung cancer. , 2020, 15, e0235611.		0
206	Origin of circulating free DNA in patients with lung cancer. , 2020, 15, e0235611.		0
207	Origin of circulating free DNA in patients with lung cancer. , 2020, 15, e0235611.		0
208	Origin of circulating free DNA in patients with lung cancer. , 2020, 15, e0235611.		0
209	Alveolar rhabdomyosarcoma with massive bone marrow infiltration and disseminated intravascular coagulation mimicking acute leukemia. EJHaem, 0, , .	1.0	0